Zydus Lifesciences Limited (ZYDUSLIFE) announced today that the United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. This product, equivalent to Climara Pro® Transdermal System, is eligible for the 180-day exclusivity period available to certain first approved applicants under the Competitive Generic Therapy (CGT) pathway. The approval marks a significant milestone for Zydus, as it expands its portfolio of generic pharmaceuticals. Estradiol and Levonorgestrel Transdermal System is primarily used to treat moderate to severe symptoms of menopause and is also used in postmenopausal women for the prevention of osteoporosis. The product will be manufactured at the group’s manufacturing plant at Moraiya, near Ahmedabad, Gujarat. This approval adds to Zydus’s growing list of approvals, now totaling 458, and brings its total ANDA filings with the USFDA to 516.

Market Potential

Estradiol and Levonorgestrel Transdermal System had annual sales of approximately USD 45.7 million in the United States as of August 2026 (IQVIA MAT). The FDA approval is expected to provide Zydus with a competitive edge in the generic hormone therapy market. The 180-day exclusivity period will help Zydus to capture a significant market share without immediate competition from other generics.

Strategic Importance

This approval is strategically important for Zydus as it continues to expand its presence in the U.S. market. The company has been actively filing ANDA applications to gain approvals for various generic drugs. The inclusion of this new product in its portfolio will enhance its market position and potentially drive growth in the coming quarters. As a result, Zydus is well-positioned to leverage this approval to further its market reach and strengthen its generic drug offerings.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock gains 1.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced today that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond its initial approval in nasopharyngeal carcinoma (NPC).

Expanding Access to Immunotherapy

Through this approval, Dr. Reddy’s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial, which demonstrated a 42% reduction in the risk of disease or death compared with chemotherapy alone.

Significant Market Opportunity

In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1% of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. With this approval, Dr. Reddy’s Laboratories Ltd. is taking a significant step in addressing this critical need.

M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said: “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that UNLOXCYT® (cosibelimab-ipdl) has received a Category 2A recommended option in the updated National Comprehensive Cancer Network® (NCCN®) guidelines for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation. This marks a significant milestone, reflecting the growing body of clinical evidence supporting UNLOXCYT.

Clinical Evidence and Patient Benefits

The evidence submitted to NCCN was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable with a median follow-up of 24.1 months and a median duration of response not yet reached. Importantly, fewer than 1% of patients experienced high-grade immune-mediated adverse reactions, which is crucial for this patient population.

Impact on Patient Access

The NCCN Guidelines play a vital role in helping physicians evaluate appropriate treatment options for patients across different disease settings. This designation ensures that appropriate patients can receive this treatment without unnecessary access barriers, offering a therapy that provides durable responses with a low rate of high-grade adverse reactions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.